N/A N=95 Promoting Cervical Cancer Screening for Emergency Department Patients
Cervical Cancer
Primary: Number of Participants Who Scheduled or Completed Cervical Cancer Screening — 28; 21 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=33 HPV DNA Testing Through Mobile Mammography Unit
Cervical Cancer
Primary: Acceptability of Self-Collection Paired With Mobile Mammography — 33 Participants
N/A N=16,231 Randomized Trial of In-Home Cervical Cancer Screening in Underscreened Women
Cervical Cancer
Primary: Number of Participants Diagnosed With Cervical Epithelial Neoplasia Grade 2 or Worse — 12; 8 Participants
N/A N=2,474 Prospective Evaluation of Self-Testing to Increase Screening
Cervical Cancer · Human Papillomavirus Infection
Primary: Primary Screening Participation — 144; 340; 381 Participants
N/A N=1,100 Conducting Outreach to Improve Cervical Cancer Screening Rates Among Underscreened Patients
Uterine Cervical Neoplasms
Primary: Proportion of Patients Who Receive a Pap Test at End of Follow up — 44; 50; 53; 59 Participants
N/A N=57 Screening for HPV and Cervical Cancer in Young Women With Perinatally Acquired HIV
HIV Infections · Human Papillomavirus Infection · Cervical Cancer
Primary: Prevalence of Abnormal Cervical Cytology — 12 Participants
N/A N=802 Multilevel HPV Self-Testing Intervention for the Increase of Cervical Cancer Screening Among Women in Appalachia
Cervical Carcinoma · Human Papillomavirus Infection
Primary: Effectiveness of Human Papillomavirus (HPV) Intervention — 69; 17 Participants
N/A N=159 Screening for Cervical Intraepithelial Neoplasia Using Self-collected Menstrual Blood
HPV - Anogenital Human Papilloma Virus Infection
Primary: Agreement Between Modified Menstrual Pad and Clinician-Collected Specimen — 93.5; 100; 100 percentage of agreement
N/A N=2,661 Optimal Strategy for the Management of ASCUS Cytology in Health Care Services of Medellin, Colombia
Cervical Abnormalities · Cervical Intraepithelial Neoplasia Grade 2/3 · Cervical Cancer
Primary: Cumulative Number of Participants Diagnosed by the Community Pathologist With Cervical Intraepithelial Neoplasia Grade 2 or Higher (CIN2+): "Community-based CIN2+"…
N/A N=153 Cervical Cancer Self-Collection for Southeast Asian Immigrant and Refugee Women
Cervical Cancer Screening
Primary: Number of Participants Who Obtain or Self-Report Future Desire for Cervical Cancer Screening — 59; 71 Participants
N/A N=20 Testing an Implementation Science Tool to Increase Cervical Cancer Screening in Mombasa, Kenya
Cervical Cancer
Primary: Cervical Cancer Screening — 198; 289 individuals screened — p=<0.001
N/A N=45 Cultural Acceptability and Feasibility of HPV Cervical Self Collection Aided by Lay Navigators
Human Papilloma Virus
Primary: Acceptability of At-home Self-collection for HPV Testing Among Under-screened Women in Southwest Virginia. — 45 Participants
N/A N=705 Cervical Cancer Screening Intervention Among Korean American Women
Cervical Carcinoma
Primary: Number of Women Who Receive a Pap Smear Test — 209; 30 participants — p=<0.001
N/A N=467 HPV Test-and-Treat-Strategy Versus Cytology-based Strategy for Prevention of CIN2+ in HIV-Infected Women
HIV-1 Infection
Primary: Cumulative Rate of Cervical Intraepithelial Neoplasia (CIN2+) (CIN2, CIN3 or Invasive Cancer) by Week 130 — 24.9; 26.5 Events per 100 persons
N/A N=32,771 Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial
Uterine Cervical Neoplasm · Uterine Neoplasms · Genital Neoplasms, Female
Primary: Screening Completion by Outreach Approach and Prior Screening Behavior — 3671; 3960; 1482; 3956 Participants — p=0.05
N/A N=222 Patient Self-sampling of HPV to Screen for Cervical Cancer
Human Papilloma Virus
Primary: Concordance of Patient-collected and Clinician-collected Samples to Detect HPV Infection — 98; 94; 99; 95 Total Percentage Agreement
Phase 2 N=198 Feasibility of Delphi Screener for Cervical Cytology
Cervical Neoplasia
Primary: Sensitivity and Specificity — 0.86; 0.80 % of participants correctly diagnosed
N/A N=48 Multilevel Intervention Based on Colorectal Cancer (CRC) and Cervical Cancer Self-screening in Rural, Segregated Areas
Colorectal Cancer Screening · Cervical Cancer Screening
Primary: Difference in Percentage of Participants Who Completed Any Cervical PLUS Colorectal Cancer Screening Tests — 18; 1 Participants
N/A N=6,013 Evaluation of Human Papilloma Virus (HPV) Self-testing to Increase Screening Uptake
Cervical Intraepithelial Neoplasia
Primary: Screening Uptake — 2519; 0; 2618; 599 participants
N/A N=1,250 HPV-Based Screen-and-Treat Demonstration Project in Lilongwe
HPV Infection · Cervical Cancer · HIV Infections
Primary: Same-day Visual Inspection With Acetic Acid (VIA) Rate — 469; 459 Participants
N/A N=756 Pap Smear Collection With the Papette Brush
Cervical Cancer Screening
Primary: Specimen Adequacy — 335; 371 Participants — p=.75
Phase 3 N=12,167 Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)
Cervical Cancer · Genital Warts
Primary: Incidence of the Composite Endpoint of Human Papillomavirus (HPV) 16/18-related Cervical Intraepithelial Neoplasia (CIN) 2 or Worse in the Base Study — 0.0; 0.4…
N/A N=3,367 HPV Self-Sampling in Somali Women (Isbaar Project)
Cervical Cancer · Papillomavirus Infection · Uterine Diseases
Primary: Difference-in-difference Comparison — 1.8 Hazard ratio
N/A N=964 St. Joe's Invitation Effectiveness Study
Cervical Cancer Screening
Primary: Percentage of Cervical Cancer Screening — 40; 95 Participants
N/A N=667 Feasibility and Acceptability of Offering Self-sampling to Non-attendees in Primary Care
Cancer of the Uterine Cervix
Primary: Number of Participants Who Performed HPV Self-testing Compared to the Number of Participants Who Responded to the Invitation to Come to the Hospital for Pap Testing…
Phase 3 N=225 A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years
Infections, Papillomavirus
Primary: Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies — 125; 2; 122; 3 Participants
Phase 3 N=676 Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.
Human Papillomavirus (HPV) Infection
Primary: Number of Seroconverted Subjects for Anti-human Papillomavirus (HPV)-16 and 18 Antibodies — 130; 4; 190; 5 Participants
N/A N=82 Facilitators and Barriers to Cancer Screening: Stakeholder Perspectives on Implementation
Colorectal Cancer Screening
Primary: Facilitators and Barriers to Implementing Decision Aids, Provider Notifications, and Personal Risk Calculation Using an Electronic Health Record (EHR) to Promote…
N/A N=47,208 Evaluation of the Cobas® 4800 HPV Test for the Detection of High-grade Cervical Disease
Human Papilloma Virus (HPV)
Primary: Percentage of Participants With a Diagnosis of ≥ CIN2 — 14.0; 0.8 Percentage of participants
Phase 3 N=813 Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects
Infections, Papillomavirus
Primary: Number of Subjects Seroconverted for Anti-hepatitis A (Anti-HAV) Antibodies — 240; 242 Participants